Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04474132 · ClinicalTrials.gov registry record · NA

Point of Care Testing for Presence of Current and or Previous T. Gondii Infection

A NA study of Toxoplasma Infections, sponsored by University of Chicago.

Recruiting
Registry status
NA
Development phase
210
Enrollment target
1
Study location

NCT04474132 is a NA study of Toxoplasma Infections that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 210 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04474132, a NA study of Toxoplasma Infections, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
NA
Development phase
210 participants
Enrollment target
1
Study location

Study Summary

This is part of a feasibility study to compare the predicate standard FDA cleared test for serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by LD Bio Diagnostic. The specificity and sensitivity in testing serum and whole blood will be compared. This study includes 70 persons either pregnant or non pregnant. This is being done in accordance with FDA requirements for clearance of a testing device . The investigators will use a standard FDA cleared test in all studies. The FDA has suggested that the investigators submit a pre subQ for a 510K and dual CLIA waiver. This allows the investigators also to determine feasibility of use of the predicate test in conjunction with the experimental test with volunteers, including men, women, and pregnant women.

Conditions Studied

Interventions

  • DEVICE toxoplasma ICT IgG-IgM BK

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2020-08-13
Est. Completion 2026-08-20
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT04474132

The ClinicalTrials.gov registry entry for NCT04474132 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Toxoplasma Infections appearing as the primary indexed condition, and to 1 intervention - of which toxoplasma ICT IgG-IgM BK is the first listed.

NCT04474132 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04474132 about?

NCT04474132 is a clinical study titled "Point of Care Testing for Presence of Current and or Previous T. Gondii Infection". This is part of a feasibility study to compare the predicate standard FDA cleared test for serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by LD Bio Diagnostic. The specificity and sensitivity in testing serum and whole blood will be compared. This study includes 70 persons either p...

What is the current status of trial NCT04474132?

This trial is currently recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2020-08-13. Estimated completion is 2026-08-20.

What conditions does trial NCT04474132 study?

This clinical trial studies the following conditions: Toxoplasma Infections.

What interventions are being tested in trial NCT04474132?

The interventions under investigation include: toxoplasma ICT IgG-IgM BK (DEVICE).

Who is sponsoring clinical trial NCT04474132?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04474132 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.